MicroStockHub April is the start of a new month and more importantly a new quarter. Every quarter I like to review strategy and performance in my portfolio and I also like to research and find new stocks to buy that could drive portfolio gains for the rest of the year. It is getting tough to find stocks that offer value right now (and are worth buying) because the market has experienced solid gains over the past couple of months and it now trades at or near record highs. However, I have found some really in ...

Sundry Photography Gilead Sciences (NASDAQ:GILD) has been perhaps one of the most discussed biotech companies as an investment. The company effectively was the first to cure Hepatitis C, capitalizing on an incredibly strong HIV business, before competition hurt its market position substantially. Since then, the company has become known for massive acquisitions that have struggled to pan out. Despite that, it seems like the times are finally changing. The company is building an exciting new oncology business ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this HIV and hepatitis C drugmaker have returned +1.9% over the past month versus the Zacks S&P 500 composite's +3.6% change. The Zacks Medical - Biomedical and Genetics industry, to which Gilead belongs, has lost 0.7% over this period. Now the key question is: Where could the stock be ...

Gilead Sciences (GILD) closed the latest trading day at $73.41, indicating a +0.2% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 0.57%. Meanwhile, the Dow gained 0.83%, and the Nasdaq, a tech-heavy index, added 0.39%.Heading into today, shares of the HIV and hepatitis C drugmaker had gained 2.35% over the past month, outpacing the Medical sector's gain of 0.13% and lagging the S&P 500's gain of 2.97% in that time.Market participants will be closely foll ...

LAFAYETTE, Colo.--(BUSINESS WIRE)--The Center for Disease Analysis Foundation (CDA Foundation) is thrilled to announce the first-round recipients of the CDAF-Relink grant to connect Hepatitis B and C infected individuals in the United States back to care. The program is funded by an eight-million-dollar grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program. In this first round, CDA Foundation distributed a total of 2.1 million dollars to the following 14 grantees: Organizat ...

Gilead Sciences, Inc. (NASDAQ:GILD) Barclays 26th Annual Global Healthcare Conference March 13, 2024 11:15 AM ET Company Participants Andy Dickinson - CFO Conference Call Participants Carter Gould - Barclays Carter Gould Good afternoon. Welcome to Day 2 of the Barclays Global Healthcare Conference. My name is Carter Gould, covering U.S. biopharma. I am pleased to welcome Gilead Sciences to the stage. Joining us from the company, Andy Dickinson, CFO. Andy, you’re going to make some opening comments, and the ...

Gilead Sciences, Inc. (NASDAQ:GILD) Leerink Partners Global Biopharma Conference March 12, 2024 10:00 AM ET Company Participants Cindy Perettie - EVP, Kite Conference Call Participants Daina Graybosch - Leerink Partners Daina Graybosch Okay. Good morning, everyone. My name is Daina Graybosch. I am an analyst here at Leerink Partners. My team and I cover immuno-oncology and broader. And we -- one of the companies we cover is Gilead, and we're really excited today to host Cindy Perettie from Kite. Cindy Peret ...

Gilead Sciences, Inc. (NASDAQ:GILD) Leerink Partners Global Biopharma Conference March 12, 2024 10:00 AM ET Company Participants Cindy Perettie - EVP, Kite Conference Call Participants Daina Graybosch - Leerink Partners Daina Graybosch Okay. Good morning, everyone. My name is Daina Graybosch. I am an analyst here at Leerink Partners. My team and I cover immuno-oncology and broader. And we -- one of the companies we cover is Gilead, and we're really excited today to host Cindy Perettie from Kite. Cindy Peret ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Gilead’s cash tender offer for CymaBay Therapeutics, Inc. expired at 11:59 p.m. on March 8, 2024. On February 22, 2024, Gilead and CymaBay filed the Premerger Notification and Report Forms required under the HSR Act with the Federal Trade Commission and the Antitrust Division of the U.S. Departmen ...

In the latest trading session, Gilead Sciences (GILD) closed at $73.66, marking a +1.42% move from the previous day. The stock outpaced the S&P 500's daily gain of 1.03%. Meanwhile, the Dow gained 0.34%, and the Nasdaq, a tech-heavy index, added 1.51%.Prior to today's trading, shares of the HIV and hepatitis C drugmaker had lost 2.41% over the past month. This has lagged the Medical sector's gain of 2.1% and the S&P 500's gain of 3.21% in that time.Investors will be eagerly watching for the performance of G ...